Telix Pharmaceuticals Ltd — Director's Dealing 2025

Mar 5, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Tiffany Olson
Date of last notice	17 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	4-5 March 2025
No. of securities held prior to change	95,235 fully paid ordinary shares52,070 Share Appreciation Rights with a notionalexercise price of $4.95 expiring 18 May 2026(TLXO0014)
Class	Fully paid ordinary shares
Number acquired	11,315
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Average price of $28.23 per share

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	106,550 fully paid ordinary shares
	52,070 Share Appreciation Rights with a notional
	exercise price of $4.95 expiring 18 May 2026
	(TLXO0014)
Nature of change	On-market trade
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buy-
back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest	N/A
related prior to change
Note: Details are only required for a contract in relation to which the
interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated
valuation
Interest after change	N/A

3 –[+] Closed period Part

	3 –+Closed period Part	3 –+Closed period Part	3 –+Closed period Part
	Were the interests in the securities or contractsdetailed above traded during a+closed periodwhere prior written clearance was required?			No
	If so, was prior written callow the trade to proce	learance provideded during this peri	to	N/A
			od?
If prior written clearancdate was this provided?	If prior written clearancdate was this provided?	e was provided, on	what	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 2